These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 25806108)

  • 1. New perspective on targeting the tumor suppressor p53 pathway in the tumor microenvironment to enhance the efficacy of immunotherapy.
    Guo G; Cui Y
    J Immunother Cancer; 2015; 3():9. PubMed ID: 25806108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunomodulatory Function of the Tumor Suppressor p53 in Host Immune Response and the Tumor Microenvironment.
    Cui Y; Guo G
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27869779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interactions between the tumor suppressor p53 and immune responses.
    Menendez D; Shatz M; Resnick MA
    Curr Opin Oncol; 2013 Jan; 25(1):85-92. PubMed ID: 23150340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor effect of intratumoral administration of bone marrow-derived dendritic cells transduced with wild-type p53 gene.
    Murakami T; Tokunaga N; Waku T; Gomi S; Kagawa S; Tanaka N; Fujiwara T
    Clin Cancer Res; 2004 Jun; 10(11):3871-80. PubMed ID: 15173096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Tumor suppressor gene p53: mechanisms of action in cell proliferation and death].
    Mendoza-Rodríguez CA; Cerbón MA
    Rev Invest Clin; 2001; 53(3):266-73. PubMed ID: 11496714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 and lung cancer.
    Brambilla E; Brambilla C
    Pathol Biol (Paris); 1997 Dec; 45(10):852-63. PubMed ID: 9769949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic tumor suppression by coexpression of FUS1 and p53 is associated with down-regulation of murine double minute-2 and activation of the apoptotic protease-activating factor 1-dependent apoptotic pathway in human non-small cell lung cancer cells.
    Deng WG; Kawashima H; Wu G; Jayachandran G; Xu K; Minna JD; Roth JA; Ji L
    Cancer Res; 2007 Jan; 67(2):709-17. PubMed ID: 17234782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DDX3 loss by p53 inactivation promotes tumor malignancy via the MDM2/Slug/E-cadherin pathway and poor patient outcome in non-small-cell lung cancer.
    Wu DW; Lee MC; Wang J; Chen CY; Cheng YW; Lee H
    Oncogene; 2014 Mar; 33(12):1515-26. PubMed ID: 23584477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rescue of the p53 tumor suppressor by a rationally designed molecule.
    Selivanova G; Fersht A
    Discov Med; 2004 Feb; 4(20):28-30. PubMed ID: 20705015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of p53 in anti-tumor immunity and response to immunotherapy.
    Carlsen L; Zhang S; Tian X; De La Cruz A; George A; Arnoff TE; El-Deiry WS
    Front Mol Biosci; 2023; 10():1148389. PubMed ID: 37602328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insights into wild-type and mutant p53 functions provided by genetically engineered mice.
    Donehower LA
    Hum Mutat; 2014 Jun; 35(6):715-27. PubMed ID: 24415648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. YY1 inhibits the activation of the p53 tumor suppressor in response to genotoxic stress.
    Grönroos E; Terentiev AA; Punga T; Ericsson J
    Proc Natl Acad Sci U S A; 2004 Aug; 101(33):12165-70. PubMed ID: 15295102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolution of p53 in hypoxia-stressed Spalax mimics human tumor mutation.
    Ashur-Fabian O; Avivi A; Trakhtenbrot L; Adamsky K; Cohen M; Kajakaro G; Joel A; Amariglio N; Nevo E; Rechavi G
    Proc Natl Acad Sci U S A; 2004 Aug; 101(33):12236-41. PubMed ID: 15302922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic gene modified cell based cancer vaccines.
    Kozłowska A; Mackiewicz J; Mackiewicz A
    Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
    Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
    Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adenovirus-mediated p53 and ING4 gene co-transfer elicits synergistic antitumor effects through enhancement of p53 acetylation in breast cancer.
    Wu J; Zhu Y; Xu C; Xu H; Zhou X; Yang J; Xie Y; Tao M
    Oncol Rep; 2016 Jan; 35(1):243-52. PubMed ID: 26530780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
    Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
    Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants.
    Inga A; Resnick MA
    Oncogene; 2001 Jun; 20(26):3409-19. PubMed ID: 11423991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human monocyte-derived dendritic cells pulsed with wild-type p53 protein efficiently induce CTLs against p53 overexpressing human cancer cells.
    Tokunaga N; Murakami T; Endo Y; Nishizaki M; Kagawa S; Tanaka N; Fujiwara T
    Clin Cancer Res; 2005 Feb; 11(3):1312-8. PubMed ID: 15709203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Restoration of wild-type p53 function in human cancer: relevance for tumor therapy.
    Bossi G; Sacchi A
    Head Neck; 2007 Mar; 29(3):272-84. PubMed ID: 17230559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.